On the 25th, we developed a new molecular diagnosis source technology that can collectively diagnose multiple pathogens with a single test and applied for a patent.
A new technology called ‘C-Tag’ relates to a technology that diagnoses in real time whether a pathogen is infected based on the presence of a ‘tag’ generated in the reaction solution at the same time as the gene amplification.
Existing molecular diagnostic technology requires a gene site where two elements, a primer and a probe, each bind together to diagnose multiple pathogens at the same time.
On the other hand, the new technology developed by GeneMatrix makes it easier to simultaneously diagnose various pathogens because the tag attached to the primer also serves as the binding site of the probe.
C-tag technology can be implemented in a variety of ways, such as real-time gene amplification, microarray (DNA chip), and mass spectrometry, so it is expected to be widely used in medical fields.
By diversifying our product portfolio through C-tag technology, we are strengthening our competitiveness in the genetic diagnosis market, and as a common infectious disease, we are able to develop respiratory products such as influenza, MERS, and SARS, which are highly likely to be introduced into Korea and easily emerged from new viruses. We plan to market digestive products such as diarrhea first.